RU2013144207A - Комбинированные вакцины с пониженными дозами антигена и/или адъюванта - Google Patents
Комбинированные вакцины с пониженными дозами антигена и/или адъюванта Download PDFInfo
- Publication number
- RU2013144207A RU2013144207A RU2013144207/15A RU2013144207A RU2013144207A RU 2013144207 A RU2013144207 A RU 2013144207A RU 2013144207/15 A RU2013144207/15 A RU 2013144207/15A RU 2013144207 A RU2013144207 A RU 2013144207A RU 2013144207 A RU2013144207 A RU 2013144207A
- Authority
- RU
- Russia
- Prior art keywords
- adjuvant
- toxoid
- composition
- composition according
- iii
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title claims abstract 30
- 239000000427 antigen Substances 0.000 title claims abstract 13
- 102000036639 antigens Human genes 0.000 title claims abstract 13
- 108091007433 antigens Proteins 0.000 title claims abstract 13
- 229960005486 vaccine Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 47
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims abstract 21
- 201000005702 Pertussis Diseases 0.000 claims abstract 15
- 229960003983 diphtheria toxoid Drugs 0.000 claims abstract 13
- 229960000814 tetanus toxoid Drugs 0.000 claims abstract 12
- 230000002163 immunogen Effects 0.000 claims abstract 11
- 239000000556 agonist Substances 0.000 claims abstract 10
- 241000991587 Enterovirus C Species 0.000 claims abstract 4
- 241000700721 Hepatitis B virus Species 0.000 claims abstract 3
- 102000002689 Toll-like receptor Human genes 0.000 claims 5
- 108020000411 Toll-like receptor Proteins 0.000 claims 5
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 3
- 150000001720 carbohydrates Chemical class 0.000 claims 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- 102000016550 Complement Factor H Human genes 0.000 claims 1
- 108010053085 Complement Factor H Proteins 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 241000709701 Human poliovirus 1 Species 0.000 claims 1
- 241000709704 Human poliovirus 2 Species 0.000 claims 1
- 241000709727 Human poliovirus 3 Species 0.000 claims 1
- 241000588653 Neisseria Species 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161448226P | 2011-03-02 | 2011-03-02 | |
| US61/448,226 | 2011-03-02 | ||
| US201161565980P | 2011-12-01 | 2011-12-01 | |
| US61/565,980 | 2011-12-01 | ||
| PCT/IB2012/050989 WO2012117377A1 (en) | 2011-03-02 | 2012-03-02 | Combination vaccines with lower doses of antigen and/or adjuvant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013144207A true RU2013144207A (ru) | 2015-04-10 |
Family
ID=45852630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013144207/15A RU2013144207A (ru) | 2011-03-02 | 2012-03-02 | Комбинированные вакцины с пониженными дозами антигена и/или адъюванта |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20140112950A1 (enExample) |
| EP (1) | EP2680885B8 (enExample) |
| JP (2) | JP6191082B2 (enExample) |
| KR (1) | KR20140026392A (enExample) |
| CN (1) | CN103533954B (enExample) |
| AU (1) | AU2012222883A1 (enExample) |
| BR (1) | BR112013022397A2 (enExample) |
| CA (1) | CA2828844C (enExample) |
| ES (1) | ES2681698T3 (enExample) |
| RU (1) | RU2013144207A (enExample) |
| TR (1) | TR201811280T4 (enExample) |
| WO (1) | WO2012117377A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| AU2010290896B2 (en) | 2009-09-02 | 2014-07-03 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions including TLR activity modulators |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| MX343914B (es) | 2010-09-01 | 2016-11-18 | Glaxosmithkline Biologicals Sa | Adsorcion de inmunopotenciadores en sales metalicas insolubles. |
| WO2012032489A1 (en) | 2010-09-10 | 2012-03-15 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| US20140112950A1 (en) | 2011-03-02 | 2014-04-24 | Manmohan Singh | Combination vaccines with lower doses of antigen and/or adjuvant |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| BR112014004782A2 (pt) * | 2011-09-01 | 2017-03-21 | Novartis Ag | formulações adjuvantes de antígenos de staphylococcus aureus |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| CN104519910B (zh) * | 2012-03-07 | 2017-05-03 | 诺华股份有限公司 | 肺炎链球菌抗原的含佐剂制剂 |
| JP2015509963A (ja) * | 2012-03-08 | 2015-04-02 | ノバルティス アーゲー | Ｔｌｒ４アゴニストを含む混合ワクチン |
| JP6345603B2 (ja) | 2012-03-08 | 2018-06-20 | ノバルティス アーゲー | 追加免疫ワクチンのアジュバント化された処方物 |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| EP2892553A1 (en) | 2012-09-06 | 2015-07-15 | Novartis AG | Combination vaccines with serogroup b meningococcus and d/t/p |
| RU2662970C2 (ru) * | 2012-09-18 | 2018-07-31 | Новартис Аг | Везикулы наружной мембраны |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| US9968673B2 (en) | 2013-02-26 | 2018-05-15 | Commissariat á l'ènergie atomique et aux ènergies alternatives | Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent |
| FR3002454B1 (fr) | 2013-02-26 | 2015-04-10 | Commissariat Energie Atomique | Composition immunogene sous forme d'emulsion |
| CN105007936B (zh) | 2013-03-08 | 2018-10-02 | 扬森疫苗与预防公司 | 无细胞百日咳疫苗 |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| RU2662968C2 (ru) * | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Иммуногенная композиция против neisseria meningitidis (варианты) |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| US10872313B2 (en) | 2015-06-02 | 2020-12-22 | ROCA Medical Ltd. | Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| CN104013955B (zh) * | 2014-06-18 | 2016-02-24 | 中国科学院过程工程研究所 | 一种不含表面活性剂的水包油乳液及其用途 |
| EP3204494B1 (en) * | 2014-10-07 | 2020-04-01 | Serum Institute Of India Private Limited | Improved methods for poliovirus inactivation, adjuvant adsorption |
| AU2016221318B2 (en) | 2015-02-19 | 2020-06-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| JP2018511655A (ja) * | 2015-03-20 | 2018-04-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物 |
| US10548974B2 (en) * | 2015-06-02 | 2020-02-04 | ROCA Medical Ltd. | Therapeutic treatment kit for allergies based on DNA profiles |
| CN106075428A (zh) * | 2015-07-01 | 2016-11-09 | 北京科兴中维生物技术有限公司 | 一种免疫原性组合物及其制备方法 |
| MA42317B2 (fr) * | 2015-09-16 | 2021-11-30 | Lg Chemical Ltd | Composition de vaccin combinée pour administration multiple |
| WO2017085248A1 (fr) * | 2015-11-18 | 2017-05-26 | Commissariat à l'énergie atomique et aux énergies alternatives | Composition immunogène sous forme d'émulsion comprenant deux phases dispersées, l'une comprenant un antigène et l'autre comprenant un agent immunostimulant |
| FR3043558B1 (fr) * | 2015-11-18 | 2017-12-29 | Commissariat Energie Atomique | Composition immunogene sous forme d'emulsion comprenant deux phases dispersees, l'une comprenant un antigene et l'autre comprenant un agent immunostimulant |
| EP4112638A1 (en) | 2016-05-16 | 2023-01-04 | Access to Advanced Health Institute | Formulation containing tlr agonist and methods of use |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| CN106039301A (zh) * | 2016-06-30 | 2016-10-26 | 武汉博沃生物科技有限公司 | 肺炎球菌‑b型流感嗜血杆菌‑百白破联合疫苗的制备方法 |
| AU2017316768B2 (en) * | 2016-08-26 | 2024-04-11 | Serum Institute Of India Private Limited | Multivalent vaccine composition |
| RS65362B1 (sr) | 2016-09-02 | 2024-04-30 | Sanofi Pasteur Inc | Vakcina protiv neisseria meningitidis |
| US10183070B2 (en) | 2017-01-31 | 2019-01-22 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| GB201807303D0 (en) | 2018-05-03 | 2018-06-20 | London School Of Hygeine & Tropical Medicine | Glyconjugate vaccines |
| US12409221B2 (en) | 2018-12-24 | 2025-09-09 | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof |
| EP4034157A1 (en) | 2019-09-27 | 2022-08-03 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| CN111658611B (zh) | 2020-04-13 | 2021-06-01 | 四川大学 | 一种基于微乳的疫苗递送系统及其制备方法和应用 |
| CN111643661A (zh) * | 2020-06-08 | 2020-09-11 | 王竹林 | 新型免疫佐剂、化合物及其应用 |
| CN114917331B (zh) * | 2022-06-02 | 2025-03-28 | 金宇保灵生物药品有限公司 | 一种牛多杀性巴氏杆菌荚膜a型荚膜多糖疫苗及其制备方法 |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| ATE67769T1 (de) | 1983-01-25 | 1991-10-15 | Ciba Geigy Ag | Neue peptidderivate. |
| US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
| US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
| US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| US5204098A (en) | 1988-02-16 | 1993-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-protein conjugates |
| NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
| DE68907045T2 (de) | 1989-01-17 | 1993-12-02 | Eniricerche Spa | Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind. |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| JPH04506662A (ja) | 1989-07-14 | 1992-11-19 | アメリカン・サイアナミド・カンパニー | 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー |
| US5059258A (en) | 1989-08-23 | 1991-10-22 | Aluminum Company Of America | Phosphonic/phosphinic acid bonded to aluminum hydroxide layer |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| DE69113564T2 (de) | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. |
| US6699474B1 (en) | 1990-08-20 | 2004-03-02 | Erich Hugo Cerny | Vaccine and immunserum against drugs of abuse |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| EP0967279B1 (en) | 1992-03-02 | 2008-01-02 | Novartis Vaccines and Diagnostics S.r.l. | Helicobacter pylori cytotoxin useful for vaccines and diagnostics |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| JP4097691B2 (ja) | 1992-08-31 | 2008-06-11 | バクスター、ヘルスケア、ソシエテ、アノニム | Ｃ群髄膜炎菌に対するワクチン |
| US5425946A (en) | 1992-08-31 | 1995-06-20 | North American Vaccine, Inc. | Vaccines against group C Neisseria meningitidis |
| AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| DE69529219T2 (de) | 1994-07-01 | 2003-11-06 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Helicobacter proteine und impstoffe |
| FI972194A7 (fi) | 1994-11-24 | 1997-05-22 | Basilea Pharmaceutica Ag | Uusia bentsyylipyrimidiinejä |
| NZ311000A (en) | 1995-06-07 | 1999-04-29 | Smithkline Beecham Biolog | Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein |
| GB2324093A (en) | 1996-01-04 | 1998-10-14 | Rican Limited | Helicobacter pylori bacterioferritin |
| GB9623233D0 (en) | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
| US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| EP2261347A3 (en) | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| HK1039072A1 (zh) | 1998-05-07 | 2002-04-12 | 科里克萨有限公司 | 佐剂组合物及其使用方法 |
| CN1263510C (zh) | 1998-08-19 | 2006-07-12 | 巴克斯特健康护理股份有限公司 | 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用 |
| AU1626199A (en) | 1998-12-04 | 2000-06-26 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A vi-repa conjugate vaccine for immunization against salmonella typhi |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| JP2002539273A (ja) | 1999-03-19 | 2002-11-19 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
| CA2365914A1 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| DK1233784T3 (da) | 1999-12-02 | 2008-09-01 | Novartis Vaccines & Diagnostic | Præparater og fremgangsmåder til stabilisering af biologiske molekyler efter lyofilisering |
| DE10012370A1 (de) | 2000-03-14 | 2001-09-27 | Chiron Behring Gmbh & Co | Adjuvans für Vakzinen |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| CA2414884A1 (en) | 2000-07-03 | 2002-01-10 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
| PT2332581E (pt) | 2001-01-23 | 2015-10-16 | Sanofi Pasteur Inc | Vacina meningocócica tri- ou tetravalente de conjugados de polissacárido e crm-197 |
| US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
| EP1399131A2 (en) * | 2001-06-08 | 2004-03-24 | Powderject Vaccines, Inc. | Spray freeze-dried compositions |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| FR2827605B1 (fr) | 2001-07-20 | 2004-07-16 | Pf Medicament | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| EP2168596B1 (en) | 2001-12-12 | 2012-05-23 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation against chlamydia trachomatis |
| GB0202901D0 (en) | 2002-02-07 | 2002-03-27 | Glaxosmithkline Biolog Sa | Novel vaccine |
| DK1777236T3 (en) | 2002-03-26 | 2017-02-27 | Glaxosmithkline Biologicals Sa | MODIFIED SUCCARIDES WHICH IMPROVED WATER STABILITY FOR USE AS A MEDICINE |
| GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
| CA2493690C (en) | 2002-06-13 | 2011-11-08 | New York University | Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases |
| CN1809380B (zh) | 2002-10-11 | 2010-05-12 | 启龙有限公司 | 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗 |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| US7818252B2 (en) | 2003-02-20 | 2010-10-19 | Gilat Satellite Networks, Ltd | Enforcement of network service level agreements |
| AU2004247305B2 (en) | 2003-06-16 | 2010-02-18 | Institute Of Organic Chemistry And Biochemistry, Academy Of Sciences Of The Czech Republic | Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs |
| EP1638602A1 (en) | 2003-06-23 | 2006-03-29 | Baxter International Inc. | Vaccines against group y neisseria meningitidis and meningococcal combinations thereof |
| CA2526106A1 (en) | 2003-06-26 | 2005-01-13 | Chiron Corporation | Immunogenic compositions for chlamydia trachomatis |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
| BRPI0508365A (pt) | 2004-03-02 | 2007-07-24 | Chiron Corp | composições imunogênicas para chlamydia pneumoniae |
| GB0405787D0 (en) * | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
| WO2005102049A1 (en) | 2004-03-31 | 2005-11-03 | New York University | Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases |
| JP5393978B2 (ja) | 2004-04-05 | 2014-01-22 | ゾエティス・ピー・エルエルシー | マイクロ流動化された水中油型乳剤及びワクチン組成物 |
| JP2008530245A (ja) | 2005-02-18 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 尿路病原性菌株由来の抗原 |
| SI2351772T1 (sl) | 2005-02-18 | 2016-11-30 | Glaxosmithkline Biologicals Sa | Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso |
| EP1866319B1 (en) | 2005-04-01 | 2011-11-23 | The Regents of The University of California | Phosphono-pent-2-en-1-yl nucleosides and analogs |
| US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| DK3466982T3 (da) | 2005-04-08 | 2020-08-03 | Wyeth Llc | Separation af forurenende kontaminanter fra streptococcus pneumoniae-polysaccharid ved ph-manipulation |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| EP2425853A1 (en) | 2005-04-08 | 2012-03-07 | Wyeth LLC | Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| US8133973B2 (en) | 2005-05-12 | 2012-03-13 | Novartis Vaccines And Diagnostics, S.R.L. | Immunogenic compositions for Chlamydia trachomatis |
| LT2351578T (lt) | 2005-06-27 | 2017-04-10 | Glaxosmithkline Biologicals S.A. | Vakcinų gavimo būdas |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| TW200801003A (en) | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| WO2007034916A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
| US20090105212A1 (en) | 2005-09-22 | 2009-04-23 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel adenine compound |
| US20090118263A1 (en) | 2005-09-22 | 2009-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Adenine Compound |
| TW200745114A (en) | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| EP1939198A4 (en) | 2005-09-22 | 2012-02-15 | Dainippon Sumitomo Pharma Co | NEW ADENINE COMPOUND |
| NZ567979A (en) | 2005-11-04 | 2012-02-24 | Novartis Vaccines & Diagnostic | Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7 |
| GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| US8481057B2 (en) | 2005-12-22 | 2013-07-09 | Novartis Vaccines & Diagnostics Srl | Chlamydial antigens |
| BRPI0620460B8 (pt) * | 2005-12-22 | 2021-05-25 | Glaxosmithkline Biologicals Sa | uso de composição imunogênica para bebês, e, processo para produzir uma vacina |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| JP2009528989A (ja) | 2006-02-17 | 2009-08-13 | ファイザー・リミテッド | Ｔｌｒ７変調剤としての３−デアザプリン誘導体 |
| WO2007109813A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| DE602007003596D1 (de) * | 2006-06-12 | 2010-01-14 | Glaxosmithkline Biolog Sa | Impfstoff |
| ES2401484T3 (es) * | 2006-06-15 | 2013-04-22 | Novartis Ag | Régimen de vacunación contra la gripe multidosis ahorrador de adyuvantes |
| WO2008004948A1 (en) | 2006-07-05 | 2008-01-10 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
| PT2038290E (pt) | 2006-07-07 | 2013-12-10 | Gilead Sciences Inc | Moduladores de receptor do tipo toll 7 |
| EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
| GB0616306D0 (en) | 2006-08-16 | 2006-09-27 | Novartis Ag | Vaccines |
| EA015964B1 (ru) | 2006-09-07 | 2012-01-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина |
| KR101467002B1 (ko) | 2006-10-10 | 2014-12-01 | 와이어쓰 엘엘씨 | 스트렙토코쿠스 뉴모니애 제3형 다당류의 정제 방법 |
| ES2397714T3 (es) | 2006-10-12 | 2013-03-08 | Glaxosmithkline Biologicals S.A. | Vacuna que comprende un adyuvante de emulsión de aceite en agua |
| WO2008047174A1 (en) | 2006-10-18 | 2008-04-24 | Centre National De La Recherche Scientifique | Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them |
| EP2125792B1 (en) | 2007-02-19 | 2010-12-01 | GlaxoSmithKline LLC | Purine derivatives as immunomodulators |
| AR065784A1 (es) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| EP2155743B1 (en) | 2007-05-08 | 2012-08-29 | AstraZeneca AB | Imidazoquinolines with immuno-modulating properties |
| CA2707030A1 (en) | 2007-08-03 | 2009-02-12 | Pfizer Limited | Imidazopyridinones |
| BR122016015627A2 (pt) | 2007-10-19 | 2018-10-30 | Novartis Ag | kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| US8685654B2 (en) | 2007-12-24 | 2014-04-01 | Novartis Ag | Assays for adsorbed influenza vaccines |
| ES2546213T3 (es) * | 2008-03-03 | 2015-09-21 | Novartis Ag | Compuestos y composiciones como moduladores de la actividad de TLR |
| UA105764C2 (uk) | 2008-03-24 | 2014-06-25 | 4 Сц Аг | Заміщені імідазохіноліни |
| WO2010003009A2 (en) | 2008-07-01 | 2010-01-07 | Emory University | Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors |
| US20110177117A1 (en) * | 2008-07-18 | 2011-07-21 | Normand Blais | Chimeric respiratory syncytial virus polypeptide antigens |
| JP5600104B2 (ja) | 2008-08-01 | 2014-10-01 | ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド | Ｔｏｌｌ様受容体アゴニスト処方物およびその使用 |
| TWM352127U (en) | 2008-08-29 | 2009-03-01 | Bestac Advanced Material Co Ltd | Polishing pad |
| AU2009333559B2 (en) | 2008-12-09 | 2015-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| MX338898B (es) * | 2009-02-17 | 2016-05-03 | Glaxosmithkline Biolog Sa | Vacuna contra el virus del dengue inactivado con un adyuvante libre de aluminio. |
| NZ612315A (en) | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| WO2010125480A1 (en) * | 2009-04-30 | 2010-11-04 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
| WO2010126151A1 (ja) * | 2009-05-01 | 2010-11-04 | 国立大学法人大阪大学 | 新規マラリアワクチン |
| US8609106B2 (en) | 2009-06-01 | 2013-12-17 | Novartis Ag | Combinations of pneumococcal RrgB clades |
| CA2765112A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
| JP2013502918A (ja) | 2009-08-27 | 2013-01-31 | ノバルティス アーゲー | 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| AU2010290896B2 (en) | 2009-09-02 | 2014-07-03 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions including TLR activity modulators |
| EP2498815A4 (en) | 2009-11-09 | 2014-03-19 | Nat Jewish Health | VACCINE COMPOSITION |
| AU2011232421B2 (en) | 2010-03-23 | 2015-08-13 | Novartis Ag | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| CA2796314A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
| MX343914B (es) * | 2010-09-01 | 2016-11-18 | Glaxosmithkline Biologicals Sa | Adsorcion de inmunopotenciadores en sales metalicas insolubles. |
| EP2652511B8 (en) | 2010-12-14 | 2017-06-28 | GlaxoSmithKline Biologicals SA | Flow cytometry analysis of materials adsorbed to metal salts |
| US20140112950A1 (en) | 2011-03-02 | 2014-04-24 | Manmohan Singh | Combination vaccines with lower doses of antigen and/or adjuvant |
| BR112014004782A2 (pt) | 2011-09-01 | 2017-03-21 | Novartis Ag | formulações adjuvantes de antígenos de staphylococcus aureus |
| WO2013131984A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of rabies virus immunogens |
| CN104519910B (zh) | 2012-03-07 | 2017-05-03 | 诺华股份有限公司 | 肺炎链球菌抗原的含佐剂制剂 |
| DK2822947T3 (en) | 2012-03-07 | 2016-09-19 | Glaxosmithkline Biologicals Sa | ARGINAL SALTS OF A TLR-7 AGONIST |
| JP6345603B2 (ja) * | 2012-03-08 | 2018-06-20 | ノバルティス アーゲー | 追加免疫ワクチンのアジュバント化された処方物 |
| EP2892553A1 (en) | 2012-09-06 | 2015-07-15 | Novartis AG | Combination vaccines with serogroup b meningococcus and d/t/p |
| CA2888721A1 (en) | 2012-10-25 | 2014-05-01 | Glaxosmithkline Biologicals Sa | Nicotinamide as adjuvant |
-
2012
- 2012-03-02 US US14/002,700 patent/US20140112950A1/en not_active Abandoned
- 2012-03-02 WO PCT/IB2012/050989 patent/WO2012117377A1/en not_active Ceased
- 2012-03-02 JP JP2013555984A patent/JP6191082B2/ja not_active Expired - Fee Related
- 2012-03-02 TR TR2018/11280T patent/TR201811280T4/tr unknown
- 2012-03-02 CA CA2828844A patent/CA2828844C/en active Active
- 2012-03-02 EP EP12709382.1A patent/EP2680885B8/en not_active Revoked
- 2012-03-02 BR BR112013022397A patent/BR112013022397A2/pt not_active Application Discontinuation
- 2012-03-02 CN CN201280021519.7A patent/CN103533954B/zh not_active Expired - Fee Related
- 2012-03-02 ES ES12709382.1T patent/ES2681698T3/es active Active
- 2012-03-02 KR KR1020137026063A patent/KR20140026392A/ko not_active Withdrawn
- 2012-03-02 AU AU2012222883A patent/AU2012222883A1/en not_active Abandoned
- 2012-03-02 RU RU2013144207/15A patent/RU2013144207A/ru not_active Application Discontinuation
-
2017
- 2017-05-17 JP JP2017097780A patent/JP2017197546A/ja active Pending
-
2018
- 2018-02-02 US US15/887,203 patent/US10603369B2/en active Active
- 2018-05-09 US US15/975,388 patent/US20180256695A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10603369B2 (en) | 2020-03-31 |
| US20140112950A1 (en) | 2014-04-24 |
| JP2017197546A (ja) | 2017-11-02 |
| CA2828844A1 (en) | 2012-09-07 |
| CN103533954B (zh) | 2015-09-09 |
| US20180256695A1 (en) | 2018-09-13 |
| WO2012117377A1 (en) | 2012-09-07 |
| BR112013022397A2 (pt) | 2017-09-26 |
| KR20140026392A (ko) | 2014-03-05 |
| CN103533954A (zh) | 2014-01-22 |
| AU2012222883A1 (en) | 2013-10-17 |
| CA2828844C (en) | 2020-07-14 |
| TR201811280T4 (tr) | 2018-08-27 |
| ES2681698T3 (es) | 2018-09-14 |
| EP2680885B8 (en) | 2018-07-25 |
| JP2014506916A (ja) | 2014-03-20 |
| JP6191082B2 (ja) | 2017-09-06 |
| EP2680885B1 (en) | 2018-05-30 |
| EP2680885A1 (en) | 2014-01-08 |
| US20180169204A1 (en) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506916A5 (enExample) | ||
| US10603369B2 (en) | Combination vaccines with lower doses of antigen and/or adjuvant | |
| RU2009149359A (ru) | Состав вакцин против менингита | |
| JP5281224B2 (ja) | ワクチン組成物 | |
| RU2014140521A (ru) | Адъювантные составы бустерных вакцин | |
| JP2010163453A5 (enExample) | ||
| RU2006142156A (ru) | Объединенные менингококковые конъюгаты с общим белком-носителем | |
| JP2015028032A (ja) | ワクチン | |
| RU2009134033A (ru) | Жидкие вакцины для множественных серогрупп менингококков | |
| SI2200642T1 (sl) | Formulacije meningokoknega cepiva | |
| WO2007026249A3 (en) | Multiple vaccination including serogroup c meningococcus | |
| SK288007B6 (sk) | Multivalent vaccine composition, process for its producing, and its use | |
| RU2008123006A (ru) | Получение вакцин, содержащих поверхностный антиген вируса гепатита в и поверхностно-активное вещество | |
| RU2015106745A (ru) | Иммуногенные композиции | |
| ATE480257T1 (de) | Kombinationsvakzine mit niedriger dosis eines hib-konjugats | |
| JP2015509963A5 (enExample) | ||
| RU2007138492A (ru) | Комбинированные вакцины с антигеном коклюша цельных клеток | |
| US20150125486A1 (en) | Adjuvanted formulations of pediatric antigens | |
| US20150320852A1 (en) | Conjugates for protecting against diphtheria and/or tetanus | |
| JP2022511511A5 (enExample) | ||
| ES2365557T5 (es) | Vacunas de combinación de Poliovirus inactivado | |
| TW201008577A (en) | Vaccine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161213 |